Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis

Citations of this article
Mendeley users who have this article in their library.


Objectives: In this nationwide retrospective study, we analysed species distribution, antimicrobial susceptibility and time to next occurrence of Achromobacter in Danish cystic fibrosis (CF) patients from 2000 to 2011. Methods: Thirty-four primary isolates were identified to species level and subjected to antimicrobial susceptibility testing. Effectiveness of early antimicrobial treatment was assessed by a Kaplan-Meier estimation of time to recurrence. Results: Achromobacter xylosoxidans accounted for 13 (38%) of the isolates, and an unnamed species accounted for 11 (32%) of the isolates. Meropenem, piperacillin-tazobactam and trimethoprim-sulfamethoxazole were highly active against chemotherapy-naïve Achromobacter, while ceftazidime, colistin and tobramycin were judged adequate for inhalation therapy. Fifty-five percent of 25 patients treated with inhaled ceftazidime, colistin, or tobramycin remained free of Achromobacter three years after acquisition, in contrast to 17% of 22 patients who did not receive inhaled antibiotics (P < 0.01). Conclusions: Early treatment with inhaled antibiotics may prevent or postpone chronic infection with Achromobacter in CF patients. © 2013 European Cystic Fibrosis Society.




Wang, M., Ridderberg, W., Hansen, C. R., Høiby, N., Jensen-Fangel, S., Olesen, H. V., … Nørskov-Lauritsen, N. (2013). Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. Journal of Cystic Fibrosis, 12(6), 638–643. https://doi.org/10.1016/j.jcf.2013.04.013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free